Zantac Recall Cancer Lawsuit
Zantac (ranitidine) is taken for conditions including heartburn, acid indigestion, sour stomach, gastroesophageal reflux disease (GERD), ulcers, and erosive esophagitis, among others. The FDA has recently announced the recall of Zantac and its generic formulation ranitidine due to contamination with the probable human carcinogen N-Nitrosodimethylamine (NDMA).
If you or a loved one has been diagnosed with cancer after taking Zantac or ranitidine, contact one of our Minnesota Cancer Lawyers today. Our team has over 30 years of complex litigation experience and will deliver the Gold standard advocacy you deserve.Call 800-903-1643 >
Case Quick Facts
In the Citizens’ Petition, Valisure explains that the ranitidine molecule is very unstable. As a result of the way the human body breaks down the medication, NDMA is formed inside the human body.
In January 2020, Emery Pharma filed a Citizen Petition with the FDA after it found Zantac and ranitidine products produced NDMA when stored over time or when exposed to temperatures higher than room temperature. Emery’s petition also requested the FDA recall all Zantac and ranitidine products.
Between September 2019 and April 2020, the FDA announced 16 different recalls of Zantac and ranitidine products.
On April 1, 2020, the FDA recommended the recall of all Zantac and ranitidine products sold in the United States.
What happens when you are exposed to NDMA?
NDMA is classified as a probable human carcinogen and as a known animal carcinogen. Therefore, exposure over prolonged periods of time or in high and concentrated doses to NDMA can cause a variety of types of cancer.
NDMA has been linked to the following types of cancers in medical studies:
- Bladder Cancer
- Breast Cancer
- Colorectal / Intestinal Cancer
- Esophageal Cancer
- Gastric Cancer
- Kidney Cancer
- Liver Cancer
- Lung Cancer
- Pancreatic Cancer
- Prostate Cancer
Zantac was first approved in 1983 and was manufactured by Glaxo Holdings, Ltd. (now GlaxoSmithKline). In 2004, Pfizer received FDA approval to sell over-the-counter Zantac, and rights were subsequently transferred from Pfizer to Johnson & Johnson, Boehringer Ingelheim Pharmaceuticals, and to Sanofi. Sanofi sold branded, over-the-counter Zantac until it recalled the product in October 2019. Other types of branded Zantac (the injectable solution) have been made by Teligent.
Generic versions of Zantac (ranitidine) have been manufactured and sold within the United States for years by a number of different manufacturers, including Novitium Pharma, Mylan, Sandoz, Ani Pharms, Inc., Apotex, Bedford, West-ward Pharms Int., Watson Labs, Ranbaxy, Contract Pharmacal, Sun Pharms, Industries Ltd., Heritage Pharma, Par Pharm, Wockhardt, Ltd., Dr. Reddy’s Labs, Ltd., Teva, Actavis Mid Atlantic, Perrigo, Pharm Assoc., Taro, Amneal Pharms NY, Glenmark Pharms, Inc., Breckenridge, Lannett Co., Inc., Anda Repository, Torrent, Aurobindo Pharma, Ltd., Hi Tech Pharma, Nostrum Labs, Inc., Zydus Pharms USA, Inc., Strides Pharma, Acic Pharms, Ajanta Pharma, ltd., Unique Farm Labs, Granules India Ltd., VKT Pharma PVT Ltd., and Appco Pharma, LLC.
GoldenbergLaw is currently investigating cases where an individual has taken Zantac or ranitidine and developed cancer. We have been litigating defective pharmaceutical cases for over thirty years and have the knowledge, experience and compassion you deserve.
Contact us today for a free consultation.Do I Qualify?
Partner Marlene Goldenberg Appointed to Zantac’s Litigation Plaintiff Steering Committee
In May 2020, Judge Robin L. Rosenberg from the U.S. District Court for the Southern District of Florida appointed 26 lawyers to spearhead the Zantac and Ranitidine litigation. GoldenbergLaw Partner Marlene Goldenberg was among the lawyers appointed to the Plaintiff Steering Committee (PSC) to help lead the litigation.
If you or a loved one developed cancer after taking Zantac or ranitidine, contact GoldenbergLaw today for a complementary consultation. We have extensive experience in litigating contaminated drug cases and believe strongly in promoting safety through accountability.Contact Us Call 800-903-1643
Zantac Lawsuit FAQs
If you have taken Zantac or ranitidine and been diagnosed with cancer, you may have a case against the manufacturers. Contact GoldenbergLaw today for a free case evaluation.
Zantac and ranitidine are being recalled due to contamination with the probable human carcinogen NDMA. According to Valisure’s Citizen’s Petition, all types of Zantac and ranitidine are affected by the NDMA contamination. The problem is with the molecular structure of the drug, which is consistent across all types of both branded Zantac and generic ranitidine.
Yes. On April, 1, 2020, the FDA requested the recall of all Zantac & ranitidine products from the U.S. market.
The FDA recommends that patients who take prescription versions of Zantac and ranitidine should speak with their physicians before making any changes. The FDA further noted that consumers taking over-the-counter versions of Zantac or ranitidine should cease use of these products and safety dispose of any remaining medication.
The FDA has recommended the removal of all Zantac and ranitidine products from the U.S. market. The FDA Zantac recall is the product of months of testing to determine whether the product was contaminated with the probable human carcinogen NDMA. On September 13, 2019, the FDA released a statement, indicating that “some ranitidine medicines” contain NDMA “at low levels.” FDA further indicated the agency would be examining levels and the possible risk to patients.
Since that time, Sandoz, Apotex Corporation (which also manufactured the Rite Aid, Walmart, and Walgreens brand tablets), Perrigo Company Plc, Novitium, Dr. Reddy’s (which also manufactured Sam’s Club, Kroger, Walgreens, Walmart, CVS, CDMA, HCA, Target, Thirty Madison, and GeriCare ranitidine products), Sanofi, and Lannett Company, Inc. have recalled some or all of their Zantac products. On April 1, 2020, the FDA recommended that all Zantac and ranitidine products be recalled.
Zantac and ranitidine products have been recalled from the U.S. market. Therefore we recommend speaking with your doctor about what course of action might be safest for you and your baby if you are currently taking Zantac or a ranitidine product.
Zantac has been classified as a Category B medication, meaning that it is safe for use during pregnancy. Specifically, a medication placed into Category B means that animal reproduction studies have failed to demonstrate a risk to the fetus, and there are no well-controlled studies in pregnant women. While this may sound a little frightening, there are very few medications in Category A, simply because it is exceptionally difficult to run studies on pregnant women due to ethical issues.
However, some studies have shown that NDMA can cross the placental barrier.
NDMA and other related nitrosamines (such as NDEA and NMBA) were also discovered in other medications, including valsartan and losartan somewhat recently. While the reason for the contamination in those drugs relates to the manufacturing process, as opposed to the molecular makeup of the drug, the risks of NDMA exposure can result in many of the same types of cancers and other complications.
If you have been diagnosed with cancer after using Zantac or ranitidine, you may be entitled to compensation for your injuries. Contact GoldenbergLaw for a free consultation and to learn more about the Zantac litigation.
Why Choose GoldenbergLaw?
When it comes to Zantac lawsuits, our Zantac Cancer litigation team is ready to help you discuss your options. We have over thirty years of experience representing cancer victims, let us deliver the Gold standard advocacy you deserve.
Thousands of Successful Settlements
Comprehensive Knowledge of Complex Issues
Focused on Client-Centered Solutions
Meet Your Zantac Team
Have a potential client we could help?
Call us. You’ll sleep better.